JP2019521139A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019521139A5 JP2019521139A5 JP2019501575A JP2019501575A JP2019521139A5 JP 2019521139 A5 JP2019521139 A5 JP 2019521139A5 JP 2019501575 A JP2019501575 A JP 2019501575A JP 2019501575 A JP2019501575 A JP 2019501575A JP 2019521139 A5 JP2019521139 A5 JP 2019521139A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- composition
- atoms
- compound
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 216
- 150000001875 compounds Chemical class 0.000 claims description 109
- 238000010362 genome editing Methods 0.000 claims description 72
- 108090000623 proteins and genes Proteins 0.000 claims description 70
- 210000004027 cell Anatomy 0.000 claims description 64
- 239000013078 crystal Substances 0.000 claims description 58
- 125000001153 fluoro group Chemical group F* 0.000 claims description 54
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 54
- 229910052731 fluorine Inorganic materials 0.000 claims description 49
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 48
- 102000004169 proteins and genes Human genes 0.000 claims description 42
- 150000007523 nucleic acids Chemical class 0.000 claims description 41
- 150000003839 salts Chemical class 0.000 claims description 41
- 229910052739 hydrogen Inorganic materials 0.000 claims description 40
- 239000001257 hydrogen Substances 0.000 claims description 40
- 239000002773 nucleotide Substances 0.000 claims description 38
- 125000003729 nucleotide group Chemical group 0.000 claims description 38
- 125000000623 heterocyclic group Chemical group 0.000 claims description 36
- 150000002431 hydrogen Chemical class 0.000 claims description 36
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 36
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 32
- 108020004707 nucleic acids Proteins 0.000 claims description 32
- 102000039446 nucleic acids Human genes 0.000 claims description 32
- 108091033409 CRISPR Proteins 0.000 claims description 28
- 239000013598 vector Substances 0.000 claims description 26
- 239000001361 adipic acid Substances 0.000 claims description 25
- 235000011037 adipic acid Nutrition 0.000 claims description 25
- 230000014509 gene expression Effects 0.000 claims description 24
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 22
- 229910052805 deuterium Inorganic materials 0.000 claims description 22
- 230000007018 DNA scission Effects 0.000 claims description 21
- 238000010354 CRISPR gene editing Methods 0.000 claims description 20
- 230000037361 pathway Effects 0.000 claims description 20
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims description 18
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 18
- 125000002757 morpholinyl group Chemical group 0.000 claims description 18
- 125000003566 oxetanyl group Chemical group 0.000 claims description 18
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 18
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 18
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- 230000008439 repair process Effects 0.000 claims description 15
- 230000006780 non-homologous end joining Effects 0.000 claims description 14
- 108020004414 DNA Proteins 0.000 claims description 13
- 108020005004 Guide RNA Proteins 0.000 claims description 12
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 10
- 239000012190 activator Substances 0.000 claims description 10
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 10
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 10
- 239000013603 viral vector Substances 0.000 claims description 10
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims description 8
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 8
- 230000000295 complement effect Effects 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 239000005711 Benzoic acid Substances 0.000 claims description 5
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 5
- 235000010233 benzoic acid Nutrition 0.000 claims description 5
- 239000001530 fumaric acid Substances 0.000 claims description 5
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 5
- 239000011976 maleic acid Substances 0.000 claims description 5
- 101710172824 CRISPR-associated endonuclease Cas9 Proteins 0.000 claims description 4
- 102220605874 Cytosolic arginine sensor for mTORC1 subunit 2_D10A_mutation Human genes 0.000 claims description 4
- 102000053602 DNA Human genes 0.000 claims description 4
- 108010008532 Deoxyribonuclease I Proteins 0.000 claims description 4
- 102000007260 Deoxyribonuclease I Human genes 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 101710163270 Nuclease Proteins 0.000 claims description 4
- 101000910035 Streptococcus pyogenes serotype M1 CRISPR-associated endonuclease Cas9/Csn1 Proteins 0.000 claims description 4
- 230000022131 cell cycle Effects 0.000 claims description 4
- 229940125904 compound 1 Drugs 0.000 claims description 4
- 229940125782 compound 2 Drugs 0.000 claims description 4
- 230000005782 double-strand break Effects 0.000 claims description 4
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 claims description 4
- 239000012636 effector Substances 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 238000002703 mutagenesis Methods 0.000 claims description 4
- 231100000350 mutagenesis Toxicity 0.000 claims description 4
- 239000013612 plasmid Substances 0.000 claims description 4
- 241000702421 Dependoparvovirus Species 0.000 claims description 3
- 241000713666 Lentivirus Species 0.000 claims description 3
- 241000700584 Simplexvirus Species 0.000 claims description 3
- 239000001384 succinic acid Substances 0.000 claims description 3
- 230000002103 transcriptional effect Effects 0.000 claims description 3
- 241000701161 unidentified adenovirus Species 0.000 claims description 3
- 241001430294 unidentified retrovirus Species 0.000 claims description 3
- 108020004635 Complementary DNA Proteins 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 2
- 229940126214 compound 3 Drugs 0.000 claims description 2
- 210000004748 cultured cell Anatomy 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 238000003780 insertion Methods 0.000 claims description 2
- 230000037431 insertion Effects 0.000 claims description 2
- 230000010354 integration Effects 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 230000001360 synchronised effect Effects 0.000 claims description 2
- -1 1 Chemical class 0.000 claims 10
- 238000005245 sintering Methods 0.000 claims 4
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 claims 1
- 208000009889 Herpes Simplex Diseases 0.000 claims 1
- 229940125797 compound 12 Drugs 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 108091006106 transcriptional activators Proteins 0.000 claims 1
- 230000035899 viability Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 54
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662361781P | 2016-07-13 | 2016-07-13 | |
| US201662361961P | 2016-07-13 | 2016-07-13 | |
| US62/361,961 | 2016-07-13 | ||
| US62/361,781 | 2016-07-13 | ||
| PCT/US2017/041979 WO2018013840A1 (en) | 2016-07-13 | 2017-07-13 | Methods, compositions and kits for increasing genome editing efficiency |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019521139A JP2019521139A (ja) | 2019-07-25 |
| JP2019521139A5 true JP2019521139A5 (OSRAM) | 2020-08-20 |
| JP7033583B2 JP7033583B2 (ja) | 2022-03-10 |
Family
ID=59388213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019501575A Active JP7033583B2 (ja) | 2016-07-13 | 2017-07-13 | ゲノム編集効率を高めるための方法、組成物及びキット |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11124805B2 (OSRAM) |
| EP (2) | EP4219462A1 (OSRAM) |
| JP (1) | JP7033583B2 (OSRAM) |
| CN (1) | CN109863143B (OSRAM) |
| AU (2) | AU2017295720B2 (OSRAM) |
| CA (1) | CA3030783A1 (OSRAM) |
| ES (1) | ES2938210T3 (OSRAM) |
| MA (1) | MA45670A (OSRAM) |
| WO (1) | WO2018013840A1 (OSRAM) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
| US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
| US9725710B2 (en) | 2014-01-08 | 2017-08-08 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| AU2015330699B2 (en) | 2014-10-10 | 2021-12-02 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
| EP4464338A3 (en) | 2014-11-07 | 2025-02-12 | Editas Medicine, Inc. | Systems for improving crispr/cas-mediated genome-editing |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| AU2016326711B2 (en) | 2015-09-24 | 2022-11-03 | Editas Medicine, Inc. | Use of exonucleases to improve CRISPR/Cas-mediated genome editing |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| WO2017165826A1 (en) | 2016-03-25 | 2017-09-28 | Editas Medicine, Inc. | Genome editing systems comprising repair-modulating enzyme molecules and methods of their use |
| EP4047092B1 (en) | 2016-04-13 | 2025-07-30 | Editas Medicine, Inc. | Cas9 fusion molecules, gene editing systems, and methods of use thereof |
| US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| EP4219462A1 (en) | 2016-07-13 | 2023-08-02 | Vertex Pharmaceuticals Incorporated | Methods, compositions and kits for increasing genome editing efficiency |
| JP2020513248A (ja) | 2016-10-19 | 2020-05-14 | フロデザイン ソニックス， インク．Ｆｌｏｄｅｓｉｇｎ Ｓｏｎｉｃｓ， Ｉｎｃ． | 音響による親和性細胞抽出 |
| LT3625222T (lt) | 2017-05-18 | 2021-11-10 | Idorsia Pharmaceuticals Ltd | Fenilo dariniai, kaip pge2 receptoriaus moduliatoriai |
| CN110621671A (zh) | 2017-05-18 | 2019-12-27 | 爱杜西亚药品有限公司 | 作为pge2受体调节剂的苯并呋喃及苯并噻吩衍生物 |
| TW201900180A (zh) | 2017-05-18 | 2019-01-01 | 瑞士商愛杜西亞製藥有限公司 | 嘧啶衍生物 |
| PT3625228T (pt) | 2017-05-18 | 2021-09-16 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores dos recetores de pge2 |
| EP3652312A1 (en) | 2017-07-14 | 2020-05-20 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
| US10785574B2 (en) | 2017-12-14 | 2020-09-22 | Flodesign Sonics, Inc. | Acoustic transducer driver and controller |
| CN111770921B (zh) | 2018-01-17 | 2024-03-22 | 沃泰克斯药物股份有限公司 | 用于提高基因组编辑效率的喹喔啉酮化合物，组合物，方法和试剂盒 |
| ES2980444T3 (es) | 2018-01-17 | 2024-10-01 | Vertex Pharma | Inhibidores de ADN-PK |
| US12121524B2 (en) * | 2018-01-17 | 2024-10-22 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
| AU2019266240A1 (en) * | 2018-05-07 | 2021-01-07 | President And Fellows Of Harvard College | Cell populations and gene expression associated with in vitro beta cell differentiation |
| WO2019224603A1 (en) | 2018-05-24 | 2019-11-28 | Crispr Therapeutics Ag | Methods and compositions for efficient gene deletion |
| CN110592141B (zh) * | 2018-06-13 | 2023-07-07 | 中国科学院上海有机化学研究所 | 用于调控基因编辑效率的化合物及其应用 |
| CN108949830B (zh) * | 2018-08-03 | 2021-11-26 | 福州大学 | 一种在鱼类中实现基因组编辑、精确定点基因敲入的方法 |
| EP3640329A1 (en) * | 2018-10-18 | 2020-04-22 | Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Gene editing based cancer treatment |
| JP7405485B2 (ja) * | 2018-12-12 | 2023-12-26 | ドピクサス | 部位特異的核酸を用いた核酸濃縮と続いての捕捉方法 |
| WO2020205664A1 (en) * | 2019-03-29 | 2020-10-08 | Youhealth Biotech, Limited | Compositions and methods for cellular reprogramming to rescue visual function |
| WO2020227255A1 (en) * | 2019-05-06 | 2020-11-12 | The Regents Of The University Of Michigan | Targeted therapy |
| EP4022057A1 (en) | 2019-08-27 | 2022-07-06 | Vertex Pharmaceuticals Incorporated | Compositions and methods for treatment of disorders associated with repetitive dna |
| CN112553330B (zh) * | 2019-09-26 | 2022-07-26 | 首都医科大学附属北京友谊医院 | 新型肿瘤相关转录因子zscan16及其在抑制肿瘤中的应用 |
| EP4034659A4 (en) * | 2019-09-27 | 2024-10-16 | The Broad Institute, Inc. | PROGRAMMABLE POLYNUCLEOTIDE EDITORS FOR AMPLIFIED HOMOLOGOUS RECOMBINATION |
| TW202132565A (zh) | 2019-11-01 | 2021-09-01 | 美商聖加莫治療股份有限公司 | Ｇｉｎ重組酶變異體 |
| CN110863011A (zh) * | 2019-11-28 | 2020-03-06 | 浙江大学 | 干扰猪crtc3表达的质粒及腺病毒的构建方法及其用途 |
| CN112877364B (zh) * | 2019-11-29 | 2023-07-28 | 中国医学科学院药物研究所 | 软骨下骨细胞向关节软骨细胞直接转化的重编程诱导方案 |
| CN111088290B (zh) * | 2019-12-30 | 2021-10-08 | 同济大学 | 一种杜鹃素在基因编辑中的应用 |
| WO2021166306A1 (en) * | 2020-02-19 | 2021-08-26 | Kyoto University | Production method of genome-edited cells and kit therefor |
| US20230183751A1 (en) * | 2020-05-21 | 2023-06-15 | Oxford Genetics Limited | Hdr enhancers |
| US20230183197A1 (en) * | 2020-06-01 | 2023-06-15 | Neophore Limited | Inhibitors of mlh1 and/or pms2 for cancer treatment |
| CN113897357A (zh) * | 2020-07-06 | 2022-01-07 | 北京大学 | Twist1基因编辑系统及其在制备治疗三阴性乳腺癌的产品中的应用 |
| CN114717232A (zh) * | 2020-12-22 | 2022-07-08 | 未来智人再生医学研究院(广州)有限公司 | 表达irf-1靶向抑制因子的多能干细胞及其衍生物与应用 |
| CN112750498B (zh) * | 2020-12-30 | 2022-06-24 | 同济大学 | 靶向逆转录引物结合位点从而抑制hiv病毒复制的方法 |
| WO2022182959A1 (en) | 2021-02-26 | 2022-09-01 | Vertex Pharmaceuticals Incorporated | Compositions and methods for treatment of myotonic dystrophy type 1 with crispr/slucas9 |
| WO2022182957A1 (en) | 2021-02-26 | 2022-09-01 | Vertex Pharmaceuticals Incorporated | Compositions and methods for treatment of myotonic dystrophy type 1 with crispr/sacas9 |
| CN113373148B (zh) * | 2021-06-16 | 2022-08-26 | 中国人民解放军军事科学院军事医学研究院 | 一种调控app表达的靶标位点序列及其在防治ad上的应用 |
| WO2023018637A1 (en) | 2021-08-09 | 2023-02-16 | Vertex Pharmaceuticals Incorporated | Gene editing of regulatory elements |
| AU2022375818A1 (en) * | 2021-10-29 | 2024-05-16 | Cold Spring Harbor Laboratory | Compositions and systems for rna-programable cell editing and methods of making and using same |
| CN114277119B (zh) * | 2021-12-09 | 2023-05-16 | 浙江大学医学院附属邵逸夫医院 | 一种环状RNA circ-Arsb在制备防治骨质疏松产品中的应用 |
| CN118475693A (zh) * | 2021-12-24 | 2024-08-09 | 国立大学法人大阪大学 | 利用了同源重组的基因组编辑细胞的制造方法 |
| AU2023214439A1 (en) * | 2022-02-01 | 2024-08-15 | The Brigham And Women's Hospital, Inc. | Generation of brown adipocytes from human pluripotent stem cells |
| CN114685494B (zh) * | 2022-03-16 | 2024-04-16 | 中国人民解放军军事科学院军事医学研究院 | SpCas9抑制剂的合成制备方法及其应用 |
| CN114524811B (zh) * | 2022-03-16 | 2025-01-24 | 中国人民解放军军事科学院军事医学研究院 | Lxh0307、lxh0308作为基因编辑的小分子抑制剂及其应用 |
| CN116004542A (zh) * | 2022-09-26 | 2023-04-25 | 苏州吉纳星辰生物技术有限公司 | 一种提高基因敲入效率的方法及其应用 |
| WO2024238691A2 (en) * | 2023-05-15 | 2024-11-21 | The Regents Of The University Of California | Andp gene editing system |
| WO2025024785A2 (en) * | 2023-07-26 | 2025-01-30 | University Of Utah Research Foundation | Compositions and methods for regulating znf865 |
| CN119215053B (zh) * | 2024-12-05 | 2025-04-01 | 南昌大学 | Ye6144在制备治疗乳腺癌引起的骨骼肌萎缩药物中的应用 |
| CN119752995B (zh) * | 2024-12-26 | 2025-11-28 | 中国农业科学院棉花研究所 | GhNFXL1基因在提高棉属植物耐盐性和/或耐冷性中的应用 |
Family Cites Families (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US789538A (en) | 1904-11-11 | 1905-05-09 | Colin E Ham | Dumb-bell. |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4186183A (en) | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
| US4261975A (en) | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
| US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US4774085A (en) | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| AU7979491A (en) | 1990-05-03 | 1991-11-27 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| US5436150A (en) | 1992-04-03 | 1995-07-25 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease |
| US5487994A (en) | 1992-04-03 | 1996-01-30 | The Johns Hopkins University | Insertion and deletion mutants of FokI restriction endonuclease |
| US5356802A (en) | 1992-04-03 | 1994-10-18 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease |
| US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
| US6140466A (en) | 1994-01-18 | 2000-10-31 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
| CA2681922C (en) | 1994-01-18 | 2012-05-15 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
| US6242568B1 (en) | 1994-01-18 | 2001-06-05 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
| EP0752005B1 (en) | 1994-03-23 | 2008-10-08 | Ohio University | Compacted nucleic acids and their delivery to cells |
| JP4118327B2 (ja) | 1994-08-20 | 2008-07-16 | ゲンダック・リミテッド | Ｄｎａ認識のための結合タンパク質におけるまたはそれに関連する改良 |
| GB9824544D0 (en) | 1998-11-09 | 1999-01-06 | Medical Res Council | Screening system |
| US5789538A (en) | 1995-02-03 | 1998-08-04 | Massachusetts Institute Of Technology | Zinc finger proteins with high affinity new DNA binding specificities |
| US5925523A (en) | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
| GB2338237B (en) | 1997-02-18 | 2001-02-28 | Actinova Ltd | In vitro peptide or protein expression library |
| GB9703369D0 (en) | 1997-02-18 | 1997-04-09 | Lindqvist Bjorn H | Process |
| GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| US6410248B1 (en) | 1998-01-30 | 2002-06-25 | Massachusetts Institute Of Technology | General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites |
| ATE466952T1 (de) | 1998-03-02 | 2010-05-15 | Massachusetts Inst Technology | Poly-zinkfinger-proteine mit verbesserten linkern |
| US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
| US6599692B1 (en) | 1999-09-14 | 2003-07-29 | Sangamo Bioscience, Inc. | Functional genomics using zinc finger proteins |
| US7070934B2 (en) | 1999-01-12 | 2006-07-04 | Sangamo Biosciences, Inc. | Ligand-controlled regulation of endogenous gene expression |
| US6794136B1 (en) | 2000-11-20 | 2004-09-21 | Sangamo Biosciences, Inc. | Iterative optimization in the design of binding proteins |
| US7030215B2 (en) | 1999-03-24 | 2006-04-18 | Sangamo Biosciences, Inc. | Position dependent recognition of GNN nucleotide triplets by zinc fingers |
| DE60023936T2 (de) | 1999-12-06 | 2006-05-24 | Sangamo Biosciences Inc., Richmond | Methoden zur verwendung von randomisierten zinkfingerprotein-bibliotheken zur identifizierung von genfunktionen |
| US6689558B2 (en) | 2000-02-08 | 2004-02-10 | Sangamo Biosciences, Inc. | Cells for drug discovery |
| US20020061512A1 (en) | 2000-02-18 | 2002-05-23 | Kim Jin-Soo | Zinc finger domains and methods of identifying same |
| US20030044787A1 (en) | 2000-05-16 | 2003-03-06 | Joung J. Keith | Methods and compositions for interaction trap assays |
| JP2002060786A (ja) | 2000-08-23 | 2002-02-26 | Kao Corp | 硬質表面用殺菌防汚剤 |
| US7067317B2 (en) | 2000-12-07 | 2006-06-27 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
| GB0108491D0 (en) | 2001-04-04 | 2001-05-23 | Gendaq Ltd | Engineering zinc fingers |
| US20040224385A1 (en) | 2001-08-20 | 2004-11-11 | Barbas Carlos F | Zinc finger binding domains for cnn |
| US7262054B2 (en) | 2002-01-22 | 2007-08-28 | Sangamo Biosciences, Inc. | Zinc finger proteins for DNA binding and gene regulation in plants |
| EP1476547B1 (en) | 2002-01-23 | 2006-12-06 | The University of Utah Research Foundation | Targeted chromosomal mutagenesis using zinc finger nucleases |
| US7074596B2 (en) | 2002-03-25 | 2006-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of anti-reverse mRNA cap analogues |
| US7361635B2 (en) | 2002-08-29 | 2008-04-22 | Sangamo Biosciences, Inc. | Simultaneous modulation of multiple genes |
| US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| US7972854B2 (en) | 2004-02-05 | 2011-07-05 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| DE602005011943D1 (de) | 2004-04-08 | 2009-02-05 | Sangamo Biosciences Inc | Zusammensetzungen zur behandlung von neuropathischen und neurodegenerativen erkrankungen |
| AU2005233550B2 (en) | 2004-04-08 | 2010-11-18 | Sangamo Therapeutics, Inc. | Treatment of neuropathic pain with zinc finger proteins |
| WO2007014275A2 (en) | 2005-07-26 | 2007-02-01 | Sangamo Biosciences, Inc. | Targeted integration and expression of exogenous nucleic acid sequences |
| JP5266210B2 (ja) | 2006-05-25 | 2013-08-21 | サンガモ バイオサイエンシズ インコーポレイテッド | 改変開裂ハーフドメイン |
| CN104072561B (zh) | 2007-06-19 | 2017-12-22 | 路易斯安那州州立大学及农业机械学院管理委员会 | 信使rna帽的抗‑反向硫代磷酸类似物的合成和用途 |
| WO2010017562A2 (en) | 2008-08-08 | 2010-02-11 | Mayo Foundation For Medical Education And Research | Induced pluripotent stem cells |
| CA2788560A1 (en) | 2010-02-08 | 2011-08-11 | Sangamo Biosciences, Inc. | Engineered cleavage half-domains |
| MX374399B (es) | 2012-02-29 | 2025-03-06 | Sangamo Biosciences Inc | Composiciones y sus usos para tratar y prevenir la enfermedad de huntington. |
| RS61664B1 (sr) * | 2012-04-24 | 2021-04-29 | Vertex Pharma | Inhibitori dna-pk |
| CN105188767A (zh) | 2012-07-25 | 2015-12-23 | 布罗德研究所有限公司 | 可诱导的dna结合蛋白和基因组干扰工具及其应用 |
| US9181535B2 (en) | 2012-09-24 | 2015-11-10 | The Chinese University Of Hong Kong | Transcription activator-like effector nucleases (TALENs) |
| KR102315098B1 (ko) | 2012-11-01 | 2021-10-21 | 팩터 바이오사이언스 인크. | 세포에서 단백질을 발현시키는 방법들과 생성물들 |
| CN113355357B (zh) | 2012-12-12 | 2024-12-03 | 布罗德研究所有限公司 | 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化 |
| CN105658796B (zh) | 2012-12-12 | 2021-10-26 | 布罗德研究所有限公司 | 用于序列操纵的crispr-cas组分系统、方法以及组合物 |
| EP3064585B1 (en) | 2012-12-12 | 2020-02-05 | The Broad Institute, Inc. | Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation |
| US20140310830A1 (en) | 2012-12-12 | 2014-10-16 | Feng Zhang | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| ES2536353T3 (es) | 2012-12-12 | 2015-05-22 | The Broad Institute, Inc. | Ingeniería de sistemas, métodos y composiciones de guía optimizadas para manipulación de secuencias |
| EP2931898B1 (en) | 2012-12-12 | 2016-03-09 | The Broad Institute, Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
| ES2701749T3 (es) | 2012-12-12 | 2019-02-25 | Broad Inst Inc | Métodos, modelos, sistemas y aparatos para identificar secuencias diana para enzimas Cas o sistemas CRISPR-Cas para secuencias diana y transmitir resultados de los mismos |
| BR112015013784A2 (pt) | 2012-12-12 | 2017-07-11 | Massachusetts Inst Technology | aplicação, manipulação e otimização de sistemas, métodos e composições para manipulação de sequência e aplicações terapêuticas |
| WO2014093701A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
| US11332719B2 (en) | 2013-03-15 | 2022-05-17 | The Broad Institute, Inc. | Recombinant virus and preparations thereof |
| US9885033B2 (en) * | 2013-03-15 | 2018-02-06 | The General Hospital Corporation | Increasing specificity for RNA-guided genome editing |
| EP2986709A4 (en) | 2013-04-16 | 2017-03-15 | University Of Washington Through Its Center For Commercialization | Activating an alternative pathway for homology-directed repair to stimulate targeted gene correction and genome engineering |
| CN105683379A (zh) | 2013-06-17 | 2016-06-15 | 布罗德研究所有限公司 | 用于对有丝分裂后细胞的疾病和障碍进行靶向和建模的系统、方法和组合物的递送、工程化和优化 |
| EP3011033B1 (en) | 2013-06-17 | 2020-02-19 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof |
| JP6625971B2 (ja) | 2013-06-17 | 2019-12-25 | ザ・ブロード・インスティテュート・インコーポレイテッド | 配列操作のためのタンデムガイド系、方法および組成物の送達、エンジニアリングおよび最適化 |
| KR20250012194A (ko) | 2013-06-17 | 2025-01-23 | 더 브로드 인스티튜트, 인코퍼레이티드 | 바이러스 구성성분을 사용하여 장애 및 질환을 표적화하기 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료 적용 |
| EP3011030B1 (en) | 2013-06-17 | 2023-11-08 | The Broad Institute, Inc. | Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation |
| WO2014204723A1 (en) | 2013-06-17 | 2014-12-24 | The Broad Institute Inc. | Oncogenic models based on delivery and use of the crispr-cas systems, vectors and compositions |
| DK3011031T3 (da) | 2013-06-17 | 2020-12-21 | Broad Inst Inc | Fremføring og anvendelse af crispr-cas-systemerne, vektorer og sammensætninger til levermålretning og -terapi |
| KR101448678B1 (ko) | 2013-08-12 | 2014-10-08 | 김형기 | 단추 재봉실의 뿌리감기 장치 |
| US20160237455A1 (en) | 2013-09-27 | 2016-08-18 | Editas Medicine, Inc. | Crispr-related methods and compositions |
| EP3050286A4 (en) | 2013-09-27 | 2017-05-31 | MVPindex Inc. | System and apparatus for assessing reach, engagement, conversation or other social metrics based on domain tailored evaluation of social media exposure |
| SI3424920T1 (sl) | 2013-10-17 | 2020-08-31 | Vertex Pharmaceuticals Incorporated | Kokristali (s)-n-metil-8-(1-((2'-metil-(4,5'-bipirimidin)-6-il)amino)propan-2-il) kinolin-4-karboksamida in devterirani derivati le-teh kot inhibitorji dna-pk |
| WO2016028682A1 (en) | 2014-08-17 | 2016-02-25 | The Broad Institute Inc. | Genome editing using cas9 nickases |
| ES2731437T3 (es) | 2014-11-21 | 2019-11-15 | Regeneron Pharma | Métodos y composiciones para la modificación genética dirigida mediante el uso de pares de ARN guías |
| EP4219462A1 (en) | 2016-07-13 | 2023-08-02 | Vertex Pharmaceuticals Incorporated | Methods, compositions and kits for increasing genome editing efficiency |
-
2017
- 2017-07-13 EP EP22207527.7A patent/EP4219462A1/en not_active Withdrawn
- 2017-07-13 EP EP17743188.9A patent/EP3484870B1/en active Active
- 2017-07-13 JP JP2019501575A patent/JP7033583B2/ja active Active
- 2017-07-13 CN CN201780052987.3A patent/CN109863143B/zh active Active
- 2017-07-13 CA CA3030783A patent/CA3030783A1/en active Pending
- 2017-07-13 WO PCT/US2017/041979 patent/WO2018013840A1/en not_active Ceased
- 2017-07-13 ES ES17743188T patent/ES2938210T3/es active Active
- 2017-07-13 MA MA045670A patent/MA45670A/fr unknown
- 2017-07-13 US US16/317,314 patent/US11124805B2/en active Active
- 2017-07-13 AU AU2017295720A patent/AU2017295720B2/en active Active
-
2021
- 2021-08-20 US US17/407,421 patent/US12031150B2/en active Active
- 2021-09-17 AU AU2021232813A patent/AU2021232813B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019521139A5 (OSRAM) | ||
| US20240309377A1 (en) | Reducing intron retention | |
| US20200032296A1 (en) | Methods and products for expressing proteins in cells | |
| EP3371207B1 (en) | Nucleic acids, peptides and methods | |
| JPWO2019143675A5 (OSRAM) | ||
| JP7620560B2 (ja) | 調整可能な制御のためのヒトカルボニックアンヒドラーゼ２組成物及び方法 | |
| ES2934810T3 (es) | Moléculas químicas que inhiben el mecanismo de empalme para tratar enfermedades causadas por anomalías de empalme | |
| JP2019515914A5 (OSRAM) | ||
| JP7373170B2 (ja) | ジヒドロオロト酸デヒドロゲナーゼ阻害のための方法及び組成物 | |
| JP2016538885A5 (OSRAM) | ||
| JP2018509143A5 (OSRAM) | ||
| JP2020536888A5 (OSRAM) | ||
| WO2017075465A1 (en) | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 | |
| JP2008201787A5 (OSRAM) | ||
| CN115210250B (zh) | 用于可调节性调控转录的组合物和方法 | |
| Lebek et al. | CRISPR-Cas9 base editing of pathogenic CaMKIIδ improves cardiac function in a humanized mouse model | |
| JP7630437B2 (ja) | Ｃｄ４０ｌの組成と調整可能な制御のための方法 | |
| WO2021216503A1 (en) | Aav delivery system for lung cancer treatment | |
| JP2020517270A5 (OSRAM) | ||
| WO2024192277A2 (en) | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents | |
| US20250195650A1 (en) | Methods and compositions for enhancing efficacy of therapeutic immune cells | |
| JPWO2019143677A5 (OSRAM) | ||
| CA3202459A1 (en) | Protoparvovirus and tetraparvovirus compositions and methods for gene therapy | |
| JP2023526315A (ja) | 未成熟終止コドンの阻害剤としてのキナゾリン化合物 | |
| CN119497575A (zh) | 用于现货型免疫疗法的nk细胞产品的冷冻保存 |